Clinical-stage AI protein-therapeutics company pairing ML design with an autonomous wet-lab data platform
BigHat Biosciences, founded in 2019 by Mark DePristo (ex-Google AI genomics head) and Peyton Greenside (now CEO), designs protein therapeutics by combining machine learning with an autonomous wet-lab platform that generates proprietary biological data at scale. The San Mateo company is clinical-stage: BHB810 is described as one of the first AI-designed biologics to reach the clinic, and BHB299 is also in its pipeline. On 2026-09-24 it announced a $75M Series C co-led by DFJ Growth and Premji Invest, with a16z, Section 32, Amgen Ventures, Eli Lilly and Merck GHIF among returning investors, bringing total funding to $223M. Earlier it raised a $19M Series A (2021) and a $75M Series B led by Section 32 (2022). No valuation has been disclosed.
Drug Discovery📍 San Mateo, CAFounded 2019
Current Valuation
Private
PRIVATE
IPO Outlookprivate
Is BigHat Biosciences going public?
No. BigHat Biosciences is private and has not filed to go public. There is no S-1 on file.
What is BigHat Biosciences' valuation in 2026?
No confirmed valuation is on record for BigHat Biosciences. The roster shows funding and investors where they are public; it does not estimate a mark.
Has BigHat Biosciences filed an S-1?
No public S-1 is on file for BigHat Biosciences.
Who are BigHat Biosciences' investors?
BigHat Biosciences' investors include DFJ Growth, Premji Invest, Section 32, Andreessen Horowitz, 8VC, Amgen Ventures and 10 more.
How much has BigHat Biosciences raised?
BigHat Biosciences has raised $223M in total across 3 disclosed rounds, most recently a Series C of $75M in Sep 2026.
Is BigHat Biosciences publicly traded — can you buy BigHat Biosciences stock?
No. BigHat Biosciences is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for BigHat Biosciences on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
CEO
Peyton Greenside
Founded
2019
HQ
San Mateo, CA
Total Raised
$223M
Last Round
Series C — $75M (Sep 2026) · Lead: DFJ Growth; Premji Invest (co-leads)
IPO Status
private
Fundraising Status
Series C · $75M · this month
privateTotal raised $223M3 disclosed rounds
Growth & Valuation
Capital raised per round
Charts built from publicly disclosed funding rounds and revenue estimates. Approximate, not real-time, not investment advice.
Funding History
Round
Amount
Date
Lead Investor
Post-Money
Series C
$75M
Sep 2026
DFJ Growth; Premji Invest (co-leads)
—
Series B
$75M
Jul 2022
Section 32
—
Series A
$19M
Feb 2021
—
—
Vertical Intelligence — Biotech / Gene Therapy
Biotech / Gene Therapy registry data for BigHat Biosciences has not been collected yet — the weekly vertical sweep hasn't reached this company. Check back soon.
Talent Signal
Hiring data for BigHat Biosciences has not been collected yet — the monthly talent sweep hasn't reached this company. Check back soon.
Founders & Key People
Mark DePristoPeyton Greenside
Investors
DFJ Growth · Premji Invest · Section 32 · Andreessen Horowitz · 8VC · Amgen Ventures · Eli Lilly and Company · Merck Global Health Innovation Fund · Alexandria Venture Investments · Quadrille Capital · GRIDS Capital · Discovery Ventures · Intermountain Ventures · Catalio Capital Management · LG Technology Ventures · Sigmas Group
Products
BHB810 (clinical-stage)
BHB299
Milliner AI/ML wet-lab platform
BiotechAI Drug DiscoveryAntibodiesProtein DesignClinical Stage
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.